Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Johnson_&_Johnson
|
| gptkbp:acquisitionYear |
1961
|
| gptkbp:focusArea |
immunology
infectious diseases neuroscience oncology cardiovascular diseases metabolic diseases |
| gptkbp:foundedBy |
gptkb:Paul_Janssen
|
| gptkbp:foundedYear |
1953
|
| gptkbp:headquartersLocation |
gptkb:Beerse,_Belgium
|
| https://www.w3.org/2000/01/rdf-schema#label |
Janssen Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Edurant
gptkb:Invega gptkb:Prezista gptkb:Reminyl gptkb:Risperdal gptkb:Simponi gptkb:Darzalex gptkb:Stelara gptkb:Imodium |
| gptkbp:numberOfEmployees |
over 40,000
|
| gptkbp:operatesIn |
global
|
| gptkbp:parentCompany |
gptkb:Johnson_&_Johnson
|
| gptkbp:products |
pharmaceutical drugs
|
| gptkbp:subsidiary |
gptkb:Johnson_&_Johnson
|
| gptkbp:website |
https://www.janssen.com/
|
| gptkbp:bfsParent |
gptkb:Johnson_&_Johnson
|
| gptkbp:bfsLayer |
4
|